Abstract
Genetic Engineering & Biotechnology NewsVol. 39, No. 8 Translational Medicine TutorialOncology's Fifth Pillar: Cellular ImmunotherapyFine-tuned screening protocols can be used to assess cell-based cancer therapies for potency and safety, says Charles River LaboratoriesJezrom Self-Fordham, PhD and Robert Nunan, PhDJezrom Self-Fordham, PhDJezrom Self-Fordham, PhD, is manager, immunology, and Robert Nunan, PhD, is group leader, cell biology, at Charles River Laboratories. Website: www.criver.com.Search for more papers by this author and Robert Nunan, PhDJezrom Self-Fordham, PhD, is manager, immunology, and Robert Nunan, PhD, is group leader, cell biology, at Charles River Laboratories. Website: www.criver.com.Search for more papers by this authorPublished Online:1 Aug 2019https://doi.org/10.1089/gen.39.08.20AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 39Issue 8Aug 2019 InformationCopyright © by GEN PublishingTo cite this article:Jezrom Self-Fordham, PhD and Robert Nunan, PhD.Oncology's Fifth Pillar: Cellular Immunotherapy.Genetic Engineering & Biotechnology News.Aug 2019.63-65.http://doi.org/10.1089/gen.39.08.20Published in Volume: 39 Issue 8: August 1, 2019PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
